MariMed (OTC:MRMD) reported first-quarter financial results on Thursday. The transcript from the company's first-quarter earnings call has been provided below.
Benzinga APIs provide real-time access to earnings call transcripts and financial data. Visit https://www.benzinga.com/apis/ to learn more.
View the webcast at https://app.webinar.net/MRBoXygWnPZ
Summary
MariMed Inc reported first quarter 2026 revenue of $39.5 million and a positive adjusted EBITDA of $3.6 million, reflecting strong brand performance despite challenging market conditions.
The company noted significant growth in wholesale revenue, particularly in Illinois and Delaware, with a 25% and 13% increase respectively, reinforcing their leadership in these markets.
Strategic initiatives include expansion plans in Massachusetts following the increase in dispensary cap, new store openings in Ohio, and continued licensing agreements in Pennsylvania and New York.
The company is optimistic about the impact of the rescheduling of medical cannabis, which will eliminate certain tax burdens and potentially boost future profitability.
Management highlighted the resilience and market-leading positions of their core brands, such as Betty's Eddie's and Vivations, and emphasized ongoing product innovation and customer loyalty programs as key growth drivers.
Full Transcript
Tina (Operator)
Thank you for standing by. My name is Tina and I will be your conference operator today. At this time, I would like to welcome everyone to The Merrimed Incorporated first quarter 2026 financial results call. All lines have been placed on mute to prevent any background noise. After the speaker's remarks, there will be a question and answer session. To ask a question, simply press star one on your telephone keypad. To withdraw your question, press Star one again. It is now my pleasure to turn the call over to Alex Swartz, Regional Store Director for Merrimed. You may begin.
Alex Swartz (Regional Retail Director)
Hello and good morning everyone. I'm Alex Swartz, Regional Retail Director for MariMed Inc in Maryland and Delaware. I'm honored to kick off today's 2026 first quarter earnings call. I'm privileged to work with amazing teams in both seats, deliver our high standard of exceptional service to our customers every day. Through constant collaboration with my retail teammates and MariMed's other regions, I know that every Thrive employee across 13 dispensaries is dedicated to doing the same thing. We have a unified brand, but more importantly, we have a unified mission. And it's a huge part of what I believe makes Thrive the dispensary of choice for so many people. Joining the call today are John Levine, our Chief Executive Officer, Ryan Crandall, our Chief Commercial Officer and Mario Tinhu, our Chief Financial Officer. This call will be archived on our investor relations website and contains forward looking statements. Actual events or results may differ materially from these forward looking statements and are subject to various risks and uncertainties. These risks are discussed in the Risk factors sections of our 10K and 10Qs available on our website. Any forward looking statements reflect management's expectations as of today and we assume no obligation to update them unless required by law. Additionally, we will refer to certain non GAAP financial measures which are reconciled in our earnings release. I will now turn the call over to John for his overview.
John Levine (Chief Executive Officer)
Thank you, Alex and good morning everyone. Last night we reported first quarter 2026 revenue of 39.5 million and positive adjusted EBITDA of 3.6 million. Additionally, we once again generated positive cash flow from operations. That performance was the result of our operational discipline and the strength of our brands and was achieved despite the adverse market dynamics that persist across our industry. Of particular note was our wholesale performance in Illinois and Delaware where our cultivation, manufacturing, distribution and marketing teams delivered outstanding results. We grew quarter over quarter wholesale revenue in Illinois by 25% and in Delaware by 13%, widening our leadership position in Delaware, where we are already the number one wholesaler. In fact, our products maintain market leading positions across all of our core markets. Betty's Eddies was once again the number one selling edible across Illinois, Massachusetts, Maryland and Delaware combined and our VivaSana powdered drink mix maintained a top five share across the same states. Brian is going to provide a deeper dive into our first quarter results in each of our markets. I'll now turn to the status of our primary growth drivers I have outlined during our March earnings call In Pennsylvania, our licensing partner is awaiting state approval of our products and packaging. We remain confident about the revenue potential of our brands in Pennsylvania, especially with adult use sales likely to commence in the near future as well as our success to date in neighboring states of Maryland and Delaware. In New York, we remain on schedule with our plan there. Construction has begun on the processing kitchen we are building with our licensed partner in the Bronx. We're forecasting licensing revenue generation in both states early next year while doing everything in our control to help speed up this timeline. In Maine, where we also maintain a licensing agreement, distribution of Betty's Eddy's continues to expand. Our commercial partner began sales during the fourth quarter of 2025 and has continued to sell into new dispensaries through the first quarter. Licensing allows us to generate revenue and expand our distribution in capital efficient manner. We will continue to pursue additional agreements in tandem with M and A, which remains a focused avenue of growth for meramed to that point. We are excited about recent developments in Massachusetts where the dispensary limit cap has increased from three to six. We're very interested in pursuing opportunities to add additional stores in our home state.
John Levine (Chief Executive Officer)
Our dispensary footprint will expand in Ohio first, where we're leveraging our second retail license there to open a new Thrive location in the Columbus area. We anticipate that store will open before the end of the year. We also look forward to the benefits that the recent rescheduling of medical cannabis will have on meramed and the nation near term. It locks in the elimination of 280E related taxes for medical portion of our business. There are still many questions to be answered about the rescheduled, but make no mistake, this is the single biggest piece of federal drug reform in our country's history and we're thankful for the administration for getting it done. For me, it's particularly personal moment. Bob Feierman and I founded MariMed Inc more than a decade ago as a medical cannabis company born out of a passion, belief and in the plant's medicinal value. In fact, our name Meramid was created as shorthand for marijuana medicine. I am beyond grateful that the federal government has finally acknowledged what we've always known about the plant's medicinal value. That said, this is only step one.
John Levine (Chief Executive Officer)
We are hopeful that the rescheduling of recreational cannabis will will soon follow. In the meantime, we are in the process of registering with the DEA and we will keep our eyes on the Treasurer's guidance with respect to the details about the implementation of 280e tax relief to our investors. Thank you for your continued support. Our equity remains significantly undervalued. Given the strength of our balance sheet, the fact that we own our real estate and the value of our brands, we are confident it is only a matter of time before the markets appreciate what we have created at Meramed and the bright future ahead of us.
John Levine (Chief Executive Officer)
I'll now turn the call over to Ryan.
Ryan Crandall (Chief Commercial Officer)
Thanks John and good morning everyone. Let me walk you through our revenue performance at a high level and then across each of our core markets, our sales, marketing and operations teams delivered another strong quarter with wholesale revenue increasing 4% year over year and declining 1% sequentially. Several factors drove our year over year wholesale performance. First, we maintained deep penetration with coverage in 84% of available storefronts across our core markets on a trailing year basis.
Ryan Crandall (Chief Commercial Officer)
Second were the contributions of our Illinois and Delaware teams which I'll review in my state to state rundown. The sequential decline was expected and consistent with seasonal trends the industry experiences each year from Q4 to Q1. Turning to retail, we achieved year over year growth of 5% during the first quarter and a 7% decline sequentially. Primary contributors to the year on year growth were Delaware's adult use expansion that occurred mid year, significant growth that we achieved at our Upper Marlboro store in Maryland, and continued growth of our loyalty program which accounted for approximately 80% of our overall retail revenue.
Ryan Crandall (Chief Commercial Officer)
We grew our membership count by 10% during the first quarter of 2026. That's significant because the average basket of our members was 2% higher than non members and during the quarter an improvement of 100 basis points versus last quarter. We believe it's directly attributable to the personalized offerings we're now delivering through the new Thrive app we launched during the quarter. Turning to our individual markets in Delaware, wholesale sales continued to grow since the commencement of adult use sales in August of last year, increasing 13% sequentially and 373% year over year.
Ryan Crandall (Chief Commercial Officer)
On a pro forma basis, our brand portfolio again achieved the number one overall market share position in the quarter with Betty's Eddies and Bubbies and VivaSana all owning the top spot in their respective categories and the combination of Nature's Heritage and First Date branded flower captured the number one spot in the flower category. At retail, revenue declined 12% sequentially and increased 24% year on year on a pro forma basis. The sequential decline was in line with our expectations given the seasonality of that market.
Ryan Crandall (Chief Commercial Officer)
In Massachusetts, wholesale revenue increased 1% year on year and decreased 4% sequentially according to Hoodie. We outperformed the industry in the state both year over year and sequentially on the strength of our brands. Betty's Eddies and Bubbies Baked maintain the number one sales position in their respective edible categories, and Nature's Heritage Concentrates captured the number one position up from number four at the end of Q4 vivations, nature's heritage free Rolls and In House Gummies all once again ranked in the top 10 in their respective categories.
Ryan Crandall (Chief Commercial Officer)
Our retail revenue declined 9% year on year and 10% sequentially in Massachusetts, where average order volume decreased approximately $2 per basket during the quarter. We will continue to double down and refine our loyalty program, our new Thrive app, and our digital and in store customer experiences to drive new customer engagement and existing customer retention. In Maryland, wholesale sales declined 12% year on year and 8% sequentially, the result of isolated production issues that we have already resolved and are recovering from this quarter.
Ryan Crandall (Chief Commercial Officer)
The resolve of our brand shined through during the quarter with Betty's Eddies, Bubbies, Baked VivaSana and and In House Gummies all ranking in the top three in their respective categories by market share. Retail revenue in Maryland declined 5% year over year but increased 24% sequentially, with our Upper Marlboro store continuing to outperform expectations. Turning to Illinois, where we began distributing our brands in a crowded market just a few years ago, wholesale revenue increased 22% year on year and increased 25% sequentially.
Ryan Crandall (Chief Commercial Officer)
Our standout performers were once again Betty's Eddies, which was the 13th best selling edible in the state during the first quarter, and VivaSana, which maintained its number six ranking among beverages. Notably, Nature's Heritage Flower, which didn't launch in Illinois until late 2024, cracked the top 50 flower brands in the state for the first time, moving up 15 places from 61 to 46. Retail sales in Illinois declined 10% year on year and 2% sequentially, principally due to AOV pressure. In summary, I'm pleased to see our brands continue to capture meaningful share where they're available While competitive brands come and go, our core products have stood the test of time for more than a decade, quarter after quarter and year after year. Regardless of changes in the competitive landscape or market dynamics like price compression, Betty's Natures and our other brands have shown the resilience, the consumer trust and the staying power that the world's most beloved CPG brands must have to defend their turf. But we are not standing pat. We are continuing to lean in on our product innovation to grab more market share. To that point, we've got a number of new line extensions and limited time special SKUs scheduled to roll out soon that will continue to gain new customers and and create deeper loyalty with our existing base. Before handing the call over to Mario for his financial review, I want to thank our teams for executing well within a challenging environment.
Mario Tinhu (Chief Financial Officer)
Thank you Ryan and good morning everyone. Turning to our financial Results for the first quarter, revenue for Q1 was 39.5 million, reflecting expected seasonal softness sequentially while continuing to grow year over year on a sequential basis, revenue declined 2.2 million or 5.2% compared to Q4. This decline was primarily driven by lower retail volume which was expected due to seasonality. AOV remains stable and across our markets we continue to see healthy unit demand, particularly in wholesale where increased distribution and brand penetration are driving volume growth within wholesale. Lower realized pricing in Delaware was partially offset by stronger unit volumes, particularly in that state as well as in Illinois. On a year over year basis, revenue increased 1.6 million or 4.2%, driven by continued retail expansion including adult use in Delaware and increased penetration in wholesale distribution. These gains more than offset lower pricing in our more mature markets. Overall, our revenue performance reflects continued underlying demand for our brands, stable market share and the strength of our wholesale platform. Importantly, this demonstrates the resilience of our model with volume growth and distribution gains helping to offset a more competitive pricing environment. Gross profit was 15.8 million with a gross margin of 40.1% on a sequential basis. Gross margin was relatively stable increasing approximately 20 basis points. This reflects continued operational discipline with retail performance and contributions from our Delaware operations largely offsetting expected mix shifts towards wholesale On a year over year basis. Gross margin declined approximately 110 basis points reflecting mix shifts towards wholesale, partially offset by retail margin improvement and operational efficiencies. Overall, we continue to maintain margins at or above 40% supported by strong brand positioning, disciplined cost management and efficiencies. Across our vertically integrated platform. Operating expenses were 14.4 million on a sequential basis. Operating expenses decreased slightly by approximately approximately 100,000. On a year over year basis, operating expenses declined by approximately 500,000 driven by lower bad debt expense and reduced marketing spend partially offset by investments in infrastructure including IT and finance capabilities. Operating income was 1.4 million in Q1 compared to 2.4 million in Q4, reflecting the impact of lower revenue and margin pressure. Sequentially on a year over year basis, operating income improved significantly from 700,000, demonstrating improved scale and cost discipline. Adjusted EBITDA was 3.6 million representing an EBITDA margin of 9%. On a sequential basis, EBITDA declined by approximately 800,000, primarily driven by lower revenue and mix along with modest increases in personnel related expenses. On a year over year basis, EBITDA increased by approximately 1.1 million with margin expanding from 7% to 9%, reflecting revenue growth, improved operating leverage and lower bad debt expense. Taken together, these results highlight improving operating leverage in the business. As we scale revenue, we are maintaining cost discipline which is translating into stronger year over year profitability. GAAP net loss for the quarter was 3.8 million compared to a net loss of 4.6 million in Q4, driven primarily by an accounting gain we recognized on the refinancing of our legacy Series B preferred stock and by improved operating performance on a year over year basis, GAAP net income improved significantly from the loss of 5.4 million in the first quarter of 2025, reflecting both stronger operating results in 2026 and a non recurring bad debt accounting write off taken in 2025. Turning to our balance sheet and liquidity, we ended the quarter with 7.9 million in cash and cash equivalents down 1 million from 8.9 million at the end of 2025. We generated positive operating cash flow in the quarter while investing modestly at approximately 800,000, primarily related to targeting capital expenditures and license renewals. From a capital and finance perspective, after restructuring the Series B preferred shares with Navy Capital, our current liquidity position will provide sufficient flexibility to support operations and execute on our near term growth initiatives. Overall Q1 results reflect continued year over year growth supported by retail expansion and wholesale distribution gains. Stable gross margins demonstrating the strength of our model despite a more competitive pricing environment and targeted capital allocation to fuel our growth. As John mentioned, we are thrilled with the rescheduling News announced on April 22. Approximately 20% of our first quarter retail revenue were medical sales. Therefore, this change should drive an immediate benefit from a tax perspective. Pending further movements in Washington and further guidance on implementation including timing and any transitional considerations, we will continue to monitor developments including the outcome of the planned mid year hearings. In the meantime, we remain focused on execution and believe Merrimet is well positioned to benefit.
John Levine (Chief Executive Officer)
As clarity emerges, I'll now turn it over to John for closing remarks. Thank you, Mario. Before we take questions, I want to thank our employees. They are what fuels my optimism about our future every day. Their tireless efforts and contributions are the backbone of our success. Operator, you can now open the line for questions as a reminder.
Tina (Operator)
To ask a question, simply press star1 on your telephone keypad. Again, that is star1 to ask a question. And our first question comes from the line of Pablo Zwanek with Zwanek and Associates. Please go ahead.
Pablo Zwanek
Thank you and good morning everyone. John, can you expand on the how rescheduling as it's been announced, how does that change your strategy? Does it make you I know that M and A is part of a growth strategy, but does this make you more acquisitive or more intent on growing through M and A? And if you can give nuance there in terms of growing in an asset light way in terms of licensing versus actually buying businesses and hard assets in other states. Thanks. Let's start with that.
John Levine (Chief Executive Officer)
Morning. Pablo, thank you for the question and thank you for joining the call. Yes, you know, there's a few factors that have made us change a little bit our thoughts because not just the rescheduling, but also Massachusetts changing their limits here in the state. So we're looking at expanding more retail in Massachusetts now that we're able to, which will help us get the additional margins, but that will also give us the ability to also look at additional medical facilities here in Mass so that we can get to our maximum of six apiece. So we're going to look at expansion in other states the way that we still have been to add additional retail and some licensing or purchasing of other licenses in states where we can go in with the process to expand our brand and get the brands into as many states as possible. We're very excited about the opportunity in New York and Pennsylvania to bring our brands into those states. And I think that the rescheduling and the adult use in the future in Pennsylvania will be positive impact on us.
Pablo Zwanek
Okay, thank you for that. But just if you can expand on the theme of gaining depth versus, you know, entering new states. And by that I mean, for example, in those licensing states, could you actually be in a position to buy the assets to buy those businesses or is it more about entering other states? Just trying to understand the M and A part from a gaining death component versus actually entering new states
John Levine (Chief Executive Officer)
with expanding the brands. You know, manufacturing the rescheduling isn't as big of an effect. The retail would be the concentration of expanding into additional states, especially ones with medical at first because of the fact that the medical has had the conversion to a reschedule and the adult use is still under review. It's a matter of looking at the license of our products. We're still on the same schedule of looking at whether it's a partnership or if it makes more sense to go out and use our cash flow or raising money to buy additional state licenses for processing. It still hasn't changed much because the 280E on the retail side causes the fact that people won't be able to get the credits to have the cash flow if it's adult only. This is a medical only change right now and we're hopeful to see the adult use change in the near future.
Pablo Zwanek
Thank you. And then maybe for Ryan, I guess a two part question. You know, other companies are talking about more price stabilization in some markets, not necessarily everywhere. If you can, you know, discuss that in your top four mark in your top market, what are you seeing in terms of pricing and are things beginning to stabilize? If you can touch on that, let's start with that. Brian first, thanks. Sure. Pablo, thank you for the question. In terms of price stabilization, I think you really got to look at it by category and I think there are still categories that are stressed by price compression in several of these markets. I feel like when we look at Illinois we still see prices more aggressively pricing and I think there's more producers coming online. So as we look at that, I think Illinois still has a way to go. Massachusetts appears at times to have stabilized and start to recover a little bit. But you know, at the end of the day I think it's still a dogfight in Massachusetts. Maryland is still a difficult wholesale market with some of the large producers there driving price down. So on the flower side, I think there is still a rockfight going on out there in many markets. I think these the edibles have been for a large part protected. Some of the newer innovation products around infused pre rolls and some of those categories rosin tend to get a premium and tend to be a little bit more stable from a price standpoint. But then traditional vapes, traditional pre rolls, jarred flour, larger format flourish. There's still a lot of price compression in these markets. I think Delaware probably has the least amount of compression at this point, but that will be at some point in the future Right, thank you. And then staying with Ryan, in terms of retail, I mean we track what we call revenue per store by state very closely. Right. In some states, little total sales growth, but there's more stores, so it means that there's revenue per store erosion. I understand in the case of Maryland there's pretty much a cap on total stores. Right. But can you just differentiate in terms of how bad has it gotten in terms of revenue per Illinois versus Massachusetts and I guess versus Maryland. Although in the case of Maryland there is a gap. Thanks. Sure, Pablo, I appreciate the question. I think it depends on the scope of time that you look at. I think there's been erosion everywhere. I mean, I think eighths of cannabis used to be $60 an eighth, $65 an eighth in every market. And we've seen that consistent decline of both product cost as well as overall basket across markets. And I think the real the metrics that we're focused on are increasing our transactions, making sure that we increase our loyalty program, that when folks enter our store they're getting our products, that they are returning to buy them again, and that we're making sure that we're staying in touch with our customers and listening to them. So I think that's what we're really laser focused on. And ultimately, yeah, it's a challenging environment and same store sales have been impacted in a lot of places. But I think at the end of the day, the well run businesses that continue to innovate and continue to not accept mediocre results are going to be the ones that succeed in this environment. And one last one maybe for Mario, in terms of the percent of your own brands being sold in your own stores, is that where you want it to be or is there room to increase that? And if you can be specific about certain states, meaning in terms of your own thrive stores, how much is own brands versus third party brands? Thank you.
Mario Tinhu (Chief Financial Officer)
Well, Ryan could speak a little bit more to it as well, but that is a significant and a core strategy from a sales perspective. We obviously want to increase the mix of our own products in our stores and it's something we even have a dedicated person to that and focusing that across all markets. So that is a permanent strategy that we have working in our business. Okay, I can add on, Pablo, I can add on to that, Pablo, if you'd like. Yeah, I mean we are very focused on making sure that our products show up in our stores better than they show up in any store. So that's first and foremost. And then second is we are focused on making sure that, you know, we're recommending our products first and that we're giving our products every ability to sell, you know, at an increased rate over time within our stores. So that is a core area of focus. And there is a team, you know, gold on successful results there.
Pablo Zwanek
Right, thank you. And just one last one and apologies to the other people on the Q and A queue here. I mean John or Mario. With all the news flow and rescheduling, are you getting more inbounds in terms of M and A meaning more bankers reaching out or more brokers reaching out or even more companies reaching out in terms of supply of businesses available for purchase? Have those inbounds changed since the rescheduling news or not really much.
John Levine (Chief Executive Officer)
Thank you, Pablo. No, the inbounds of the rescheduling has not affected the M&A coming in. There has been no change in any banking because this is not affecting the banks. Banks, credit card companies, they're all acting the same as if it's still an illegal situation. This has only been approved for rescheduling of the medical. So there isn't the wide open change across the industry. I do think you will it as the adult use becomes rescheduled and if they pass a banking rule. So there's more to come. But right now it's more about people are seeing more deals coming in Massachusetts with the change of the licensing aspect in M&AS more than the reschedule.
Pablo Zwanek
Thank you. That's all for me. Thank you.
Tina (Operator)
Your next question comes from a line of Joe Gomes with Noble Capital Markets. Please go ahead.
Joe Gomes
Good morning. Congrats on the quarter. I'd like to start out on Massachusetts with the increase from 3 to 6. Any geographies in Mass where you would prefer to look at are still more just Boston area focused. Maybe you could touch on that first.
John Levine (Chief Executive Officer)
Yeah, Massachusetts is an exciting opportunity, but we're not going to rush into just trying to buy a license. We have to find one that fits into a good market, that the competition around it is going to be something that we feel is the right competition. There's a lot of stores that are for sale in the western part of the state along the New York border that are one of maybe 50 in an area in a small little 20 mile radius. And we don't want to go into a situation where there's an overabundance of store. We want to find markets that will be maybe on the borders of other states but also have the competition levels that are more reasonable like the existing stores that we have. Today.
Joe Gomes
Okay. And then you mentioned, pardon me, an isolated production issue in Maryland that maybe you could give us a little more color as what happened there. And are we all fixed and back to normal?
Ryan Crandall (Chief Commercial Officer)
Yeah, Joe, thank you for the question. I mean, we did have some turnover issues for some key people there that we have since recovered from. And yes, that has all been resolved and I think we are in a great position.
Joe Gomes
Okay. And then Ryan, maybe just on the loyalty program, impressive quarter over quarter increases. How many people are on the loyalty program now? And I think you mentioned like 80% of sales are now coming from members in the loyalty program. What percent of revenues are also coming from online sales.
Ryan Crandall (Chief Commercial Officer)
Sure, Joe, thank you for the question. So I can circle back with you with an exact number of the loyalty membership, but it's in the hundreds of thousands at this point of active members. And in terms of online sales, people that put in an order before they get to the store is north of 50% at this point. And as I mentioned, we just launched our new Thrive app and that app links loyalty well. And it really drives loyalty as a part of signing up for the app. So that's been a very impactful thing to driving both increased app adoption as well as increased loyalty adoption.
Joe Gomes
Okay, and one more for me, if I may. The Metropolis dispensary, I know that one has been had some competitive challenges. I don't know if you can give us an update on how that is going these days.
Ryan Crandall (Chief Commercial Officer)
Sure, Joe. Yeah, I mean Metropolis is a fantastic store for us. Very profitable store. We've got two stores that opened within a mile of us, a mile and a half of us. You know, that impact has been felt. We compete very well with those stores. And ultimately I feel like the Metropolis store has stabilized and has started to show signs of growth again.
Joe Gomes
Great, thanks. I'll get back in queue. And just to circle back on the loyalty number. Sorry, you can answer.
Ryan Crandall (Chief Commercial Officer)
Yeah, Joe, just to circle back on the loyalty number, it's just short of 400,000. It's 398,000 active members. Thank you.
Tina (Operator)
And with no further questions in queue, this does conclude our conference call. You may now disconnect.
Disclaimer: This transcript is provided for informational purposes only. While we strive for accuracy, there may be errors or omissions in this automated transcription. For official company statements and financial information, please refer to the company's SEC filings and official press releases. Corporate participants' and analysts' statements reflect their views as of the date of this call and are subject to change without notice.
Login to comment